Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib.

Autor: Saj F; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Vasudevan Nampoothiri R; Transplantation and Cellular Therapy Program, The Ottawa Hospital, University of Ottawa, Ottawa, ON Canada., Lad D; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Jandial A; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Sachdeva MUS; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Bose P; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Varma N; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Khadwal A; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Prakash G; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India., Malhotra P; Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Nehru Hospital, Room No 18, 4th Level, F Block, Chandigarh, India.
Jazyk: angličtina
Zdroj: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion [Indian J Hematol Blood Transfus] 2024 Oct; Vol. 40 (4), pp. 580-587. Date of Electronic Publication: 2024 Aug 20.
DOI: 10.1007/s12288-024-01843-6
Abstrakt: The impact of T-regulatory cells (Tregs), PD-1 + CD8 T-cells, and their dynamics during treatment with imatinib mesylate remains poorly understood in patients with chronic myeloid leukemia (CML). We conducted a prospective study on newly diagnosed, treatment-naïve adult (> 18 years old) patients with CML in the chronic phase (CP) and age- and sex-matched controls. Peripheral blood samples were collected at diagnosis and after three months of imatinib therapy to assess Tregs and PD-1 + CD8 T-cell levels using flow cytometry. The study comprised 57 patients with a median age of 39 years, including 27 males (47%). At baseline, the mean percentage of Tregs was significantly higher in CML patients (3.6 ± 0.32%) compared to controls (1.58 ± 0.21%) ( p  < 0.0001) but decreased significantly after three months of imatinib treatment (1.73 ± 0.35%) ( p  < 0.0001). Baseline Treg% exhibited positive correlations with Sokal (r = 0.29), Hasford (r = 0.33), EUTOS (r = 0.28), and ELTS (r = 0.31) risk scores ( p  < 0.05), as well as with the BCR-ABL transcript levels at three months ( p  = 0.03). Furthermore, the mean baseline percentage of PD-1 + CD8 T-cells was significantly elevated in CML patients (7.66 ± 0.36%) compared to controls (2.65 ± 0.32%) ( p  < 0.0001) and also decreased after treatment (3.44 ± 0.37%) ( p  < 0.0001). The baseline percentage of PD-1 + T-cells demonstrated positive correlations with Sokal (r = 0.26), Hasford (r = 0.27), and ELTS (r = 0.41) risk scores ( p  < 0.05). Our findings reveal a significantly higher proportion of Tregs and PD-1 + CD8 T-cells in patients with CML-CP compared to healthy controls, notably diminished following imatinib treatment. These observations suggest the potential for immunotherapy as a promising approach to managing immune exhaustion in CML patients.
Competing Interests: Conflict of interestThere are no relevant conflicts of interest to declare.
(© Indian Society of Hematology and Blood Transfusion 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz: